Barriers and Facilitators to Cancer Clinical Trial Participation: Perspectives of Patients in the ICON-3 Practice-Based Research Network, Nigeria
Authors:
- Ngozi Idemili-AronuNINgozi Idemili-Aronu
- Tara M. Friebel-KlingnerTFTara M. Friebel-Klingner
- Adaeze Chike-OkoliACAdaeze Chike-Okoli
- Ijeoma U. ItanyiIIIjeoma U. Itanyi
- Tonia C. OnyekaTOTonia C. Onyeka
- Anne F. RositchARAnne F. Rositch
- Echezona E. EzeanolueEEEchezona E. Ezeanolue
- Kimberly LevinsonKLKimberly Levinson
- 1 October 2025
- journal article
- Published by American Society of Clinical Oncology (ASCO) in JCO Global Oncology
- Vol. 11 (11) , e2500181
Abstract
PURPOSE: Africa faces a growing burden of cancer yet remains under-represented in global cancer clinical trials. This disparity limits the generation of population-specific evidence needed to improve cancer outcomes. Recruitment and retention in cancer clinical trials are particularly challenging because of various systemic and individual barriers in Nigeria. This study explores patients' perspectives on barriers and facilitators to recruitment and retention in cancer clinical trials. METHODS: A convergent parallel mixed-methods design was used, which comprised a cross-sectional survey and a descriptive qualitative approach. Participants were recruited from multiple oncology centers and secondary facilities within Nigeria’s ICON-3 Practice-Based Research Network. Quantitative data were collected through interviewer-administered questionnaires, whereas qualitative data were gathered via semistructured interviews and analyzed thematically. RESULTS: A total of 317 patients participated in the quantitative survey, 18 of whom participated in interviews. Barriers included limited understanding of clinical trials, logistical challenges such as transportation and visit frequency, distrust in researchers and the health care system, and lack of family support. Facilitators included effective communication, incentives, flexible research visits, and culturally tailored interventions. CONCLUSION: To optimize cancer clinical trial participation in low-resource settings, interventions must be tailored to local contexts, addressing structural and cultural barriers. Enhanced communication, community involvement, and supportive policies can significantly improve trial participation and outcomes.Keywords
This publication has 23 references indexed in Scilit:
- Informed Consent among Clinical Trial Participants with Different Cancer DiagnosesAJOB Empirical Bioethics, 2023
- Perception of clinical research among patients and healthy volunteers of clinical trialsEuropean Journal of Clinical Pharmacology, 2022
- A qualitative study of barriers and facilitators to adolescents and young adults’ participation in cancer clinical trials: Oncologist and patient perspectivesPediatric Blood & Cancer, 2021
- Trial-level factors affecting accrual and completion of oncology clinical trials: A systematic reviewContemporary Clinical Trials Communications, 2021
- An Analysis of Contemporary Oncology Randomized Clinical Trials From Low/Middle-Income vs High-Income CountriesJAMA Oncology, 2021
- “When Offered to Participate”: A Systematic Review and Meta-Analysis of Patient Agreement to Participate in Cancer Clinical TrialsJNCI: Journal of the National Cancer Institute, 2020
- Systematic Review and Meta-Analysis of the Magnitude of Structural, Clinical, and Physician and Patient Barriers to Cancer Clinical Trial ParticipationJNCI: Journal of the National Cancer Institute, 2019
- A Review of Barriers to Minorities’ Participation in Cancer Clinical Trials: Implications for Future Cancer ResearchJournal of Immigrant and Minority Health, 2015
- A systematic review of the factors influencing African Americans' participation in cancer clinical trialsContemporary Clinical Trials, 2013
- Barriers to recruiting underrepresented populations to cancer clinical trials: A systematic reviewCancer, 2007